UnitedHealth CFO Says Wall Street Underestimates 2027 Earnings Upside
UNH sits 48% above its 52-week low of $255.965 on elevated volume (2.5× avg).
Summary
UnitedHealth's Q3 results were already reported yesterday, but this article adds new management commentary that goes beyond the numbers. CFO Wayne DeVeydt explicitly said Wall Street may be underestimating 2027 earnings upside, citing buybacks, value-based care, modernization, and AI as tailwinds. The company also laid out Medicare Advantage star ratings targets—at least 69% of members in 4-star or better plans by 2027, rising to 75% by 2028—and expects 2026 MA margins near the top of the 2%–4% range. CEO Tim Noel reinforced confidence in sustainable growth from 2027, though he declined to provide membership guidance. These forward-looking statements add a new layer to the already-reported Q3 beat and guidance raise, giving traders a clearer view of management's multi-year outlook.
At the time of this announcement, UNH was trading at $377.98 on NYSE in the Trade & Services sector, with a market capitalization of approximately $339.1B. The 52-week trading range was $255.97 to $461.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.